Navigation Links
SuperGen Reports 2008 Second Quarter Financial Results
Date:8/4/2008

ion

in vitro. SGI-1776 induced significant tumor regression in MV-4-11

(AML) and MOLM-13 (AML) xenograft models.

-- MP-470, an early clinical-stage multi-targeted tyrosine kinase

inhibitor and Rad51 suppressor, was shown to be bioavailable and

well-tolerated in a first in human study (Abstract No. 4083). The

presentation entitled, "MP-470, a potent oral Rad51 suppressor is

safe and tolerable in first-in-human study," summarized the data

suggesting that MP-470 is well-tolerated when administered in doses

of up to 900 mg per day. Additionally, it was found that Rad51

expression is modulated in a dose-dependent manner. This is

consistent with pre-clinical studies where MP-470 was shown to

sensitize cancer cells to DNA damaging agents and radiation therapy

by suppressing Rad51, a protein responsible for repair of double

strand DNA breaks in cancer cells.

-- MP-470 was shown to effectively sensitize prostate and breast cancer

cells to erlotinib (Abstract No. 671). The presentation entitled,

"Inhibition of erlotinib resistance on HER-family tyrosine kinases

by combination with MP-470, a multi-targeted TK inhibitor in

prostate and breast cancer," highlighted data suggesting that the

combination of MP-470 and erlotinib inhibits the binding of the p85

subunit of PI3K. The poster outlined the enhanced impact of the

combination of MP-470 and erlotinib, compared to either agent alone

in reducing phosphorylation of Akt, ERK1/2, EGFR/HER1, HER2/Neu, and

HER3.

-- S-110, a DNA methyltransferase inhibitor, demonstrated an improved

in vivo activity profile over decitabine (Abstract No. 2613). The

presentation entitled, "Decitabine administered as a Dinucleotide'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Synthetic Biologics, ... anti-infective biologic and drug candidates targeting specific pathogens ... positive results from its final preclinical toxicology study ... (FDA) guidance, this bridging study was required to ... designed to prevent the devastating effects of ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Breakthrough in light sources for new quantum technology 2
... George Bush today spoke of energy during a visit ... resources, his remarks were directed toward new methods of ... oil. , ,In an address before employees at Johnson ... a new fuel cell for hybrid automobiles, he touted ...
... 65, is retiring as president and CEO of the company at ... company said on Tuesday. , ,Barr's replacement is already on hand: ... operations, has been named chief operating officer and will step up ... with the company for two decades and was involved in the ...
... all the news from DEMO '06 (if you haven't, check out ... 2006 in the "Watch Demo Videos" window and choose a company). ... inquiring minds that want to know what wasn't at DEMO. The ... look at hundreds of products and companies and bring only the ...
Cached Biology Technology:Bush praises Johnson Controls battery tech in Milwaukee visit 2Why companies don't get invited to the DEMO conference 2Why companies don't get invited to the DEMO conference 3
(Date:9/2/2014)... suburb , Observations and mapping by seismologists at ... days after the August 24 earthquake in northern California ... much damage in the region, according to a post ... Geophysical Union. , From this week,s ... Our Curiosity , Selecting where the next Mars ...
(Date:9/2/2014)... In an article in the September issue of ... Gulf of Mexico microbial communities in the aftermath ... revealing population-level responses of hydrocarbon-degrading microbes to the ... unique opportunity to study the responses of indigenous ... Surveys of genetic identifiers within cells known as ...
(Date:9/2/2014)... published paper provides a history of scientific research ... wildlife in these systems, and sets an agenda ... , The paper, "Mountain gloom and mountain glory ... change in mountain regions," appears online in the ... Charles C. Chester of Tufts University, Jodi A. ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Changing microbial dynamics in the wake of the Macondo blowout 2An uphill climb for mountain species? 2An uphill climb for mountain species? 3
... acknowledge the need to obtain their energy supply from ... how his team have developed a new anaerobic digestion ... wind turbines. These reactors use a consortium of methanogenic ... produce biogas (a mixture of methane and carbon) which ...
... Much as an anthropologist can study populations of people ... social structures, some marine microbiologists read the genome of ... environments and lifestyles. Using a relatively new ... entire genomes of different populations of the same microbe ...
... to intestinal cancer in mice More than 50% ... cytomegalovirus (HCMV) infection. For most people, infection produces no symptoms ... a long time. HCMV infects many cell types in the ... research, led by Sergio Lira, at Mount Sinai School of ...
Cached Biology News:Microscopic solutions to world's biggest problems 2Genomic comparison of ocean microbes reveals East-West divide in populations 2Genomic comparison of ocean microbes reveals East-West divide in populations 3JCI online early table of contents: Oct. 11, 2010 2JCI online early table of contents: Oct. 11, 2010 3JCI online early table of contents: Oct. 11, 2010 4JCI online early table of contents: Oct. 11, 2010 5JCI online early table of contents: Oct. 11, 2010 6JCI online early table of contents: Oct. 11, 2010 7
... a chemiluminescent signal enhancing reagent that ... the signal obtained with all ECL ... Plus is derived from a powerful, ... or chemiluminescent substrate enhancers, ChemiLucent™ Plus ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences ... peptide is (amino to carboxy terminus): S(21) - S - M ... D - E - A - I - D - K ... C(39). This peptide may be used for neutralization and ...
... for quantitative assays using recombinant proteins/antibodies ... the flexible and powerful Paraflo microfluidic ... sequences can be synthesized on-chip and ... custom sequence design. These microarrays are ...
Biology Products: